Compare Amplify Cybersecurity ETF (HACK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Sanofi SA — how do they compare? Amplify Cybersecurity ETF trades at $130.76 (market cap $3.50B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 27.2× Amplify Cybersecurity ETF's market cap, and Sanofi SA pays a 6.01% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 28 Days and Sanofi SA for 94 Days on average.
| HACK | SNY | |
|---|---|---|
Market Cap | $3.50B | $95.18B |
Volume | 341,176 | 2,995,646 |
Sector | Sector/Thematic | Health |
52-Week High | $130.76 | $52.34 |
52-Week Low | $70.69 | $39.51 |
Typical Hold Time | 28 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $130.76, up 3.93% today and near its 52-week high, reflecting strong momentum amid bullish technical signals. The ETF benefits from rising cybersecurity demand driven by AI safety concerns and recent earnings beats from holdings like CrowdStrike. Technical indicators show a bullish trend with support at $124 and resistance at $126, while short interest has surged, indicating mixed sentiment.
Outlook remains positive due to sector tailwinds from AI-driven cyber threats, but risks include high valuation sensitivity and increased short interest. The ETF's diversified exposure to cybersecurity leaders offers growth potential, though investor caution is warranted given its proximity to record highs and competitive pressures.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
